Much less is known on the effects of glucagon-like peptide-1 (GLP-1) receptor agonists, and there are no data on newer medications containing GLP-1 receptor agonists in combination with other incretin hormones on the pseudo-hypogonadism of obesity (39). This evidence concerns the gene GCG and Obesity.